Scarica l'app Stockscreener
20.62
5.15%
-1.12
Dopo l'orario di chiusura:
20.51
-0.11
-0.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Precedente Chiudi:
$21.74
Aprire:
$21.79
Volume 24 ore:
2.81M
Relative Volume:
1.38
Capitalizzazione di mercato:
$3.48B
Reddito:
$890.53M
Utile/perdita netta:
$30.57M
Rapporto P/E:
114.56
EPS:
0.18
Flusso di cassa netto:
$80.53M
1 W Prestazione:
-0.05%
1M Prestazione:
-13.94%
6M Prestazione:
+41.52%
1 anno Prestazione:
+37.10%
Intervallo 1D:
$20.46
$22.10
Intervallo di 1 settimana:
$19.69
$22.10
Portata 52W:
$13.40
$26.65
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Nome
Acadia Pharmaceuticals Inc
Settore
Industria
Telefono
858-558-2871
Indirizzo
12830 EL CAMINO REAL, SAN DIEGO
Confronta ACAD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
20.62 | 3.43B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-21 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2025-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-03-12 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-12 | Reiterato | Needham | Buy |
| 2024-01-30 | Iniziato | Robert W. Baird | Outperform |
| 2024-01-24 | Aggiornamento | Needham | Hold → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-10-10 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-11-04 | Downgrade | Goldman | Neutral → Sell |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-08-08 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-21 | Downgrade | Jefferies | Buy → Underperform |
| 2022-06-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-16 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-06-10 | Iniziato | Berenberg | Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-04-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-04-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2021-03-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Downgrade | Stifel | Buy → Hold |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-11-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-07 | Aggiornamento | Stifel | Hold → Buy |
| 2020-04-16 | Iniziato | Jefferies | Buy |
| 2020-03-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-09-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Reiterato | Needham | Buy |
| 2018-12-10 | Iniziato | Canaccord Genuity | Hold |
| 2018-09-21 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Reiterato | Stifel | Hold |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-08-06 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
The Past Five Years for ACADIA Pharmaceuticals (NASDAQ:ACAD) Investors Has Not Been Profitable - 富途牛牛
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025 - Business Wire
Real time alert setup for ACADIA Pharmaceuticals Inc. performanceBear Alert & Detailed Earnings Play Strategies - newser.com
Ranking ACADIA Pharmaceuticals Inc. among high performing stocks via toolsQuarterly Profit Report & Reliable Intraday Trade Alerts - newser.com
Using Bollinger Bands to evaluate ACADIA Pharmaceuticals Inc.July 2025 Technicals & Daily Entry Point Alerts - newser.com
How sentiment analysis helps forecast ACADIA Pharmaceuticals Inc.Rate Hike & Fast Gaining Stock Reports - newser.com
Is ACADIA Pharmaceuticals Inc. stock trading near support levelsWeekly Gains Summary & Risk Managed Trade Strategies - newser.com
ACADIA Pharmaceuticals Shows Rising Relative Price Performance; Still Shy Of Key Benchmark - Investor's Business Daily
Using flow based indicators on ACADIA Pharmaceuticals Inc.2025 EndofYear Setup & Proven Capital Preservation Methods - newser.com
Should You Be Adding ACADIA Pharmaceuticals (NASDAQ:ACAD) To Your Watchlist Today? - Yahoo
How to track smart money flows in ACADIA Pharmaceuticals Inc.2025 Trading Volume Trends & Entry Point Confirmation Signals - newser.com
How to interpret RSI for ACADIA Pharmaceuticals Inc. stockWeekly Trade Analysis & Free Risk Controlled Daily Trade Plans - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc.ACAD - cnhinews.com
Applying Elliott Wave Theory to ACADIA Pharmaceuticals Inc.Weekly Loss Report & Risk Adjusted Swing Trade Ideas - newser.com
Why ACADIA Pharmaceuticals Inc. stock could be next big winnerTrade Volume Report & Safe Entry Zone Identification - newser.com
Leerink Partnrs Issues Optimistic Outlook for ACAD Earnings - MarketBeat
Heatmap analysis for ACADIA Pharmaceuticals Inc. and competitors2025 Pullback Review & Weekly Market Pulse Alerts - newser.com
How high can ACADIA Pharmaceuticals Inc. stock go2025 Institutional Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
Detecting support and resistance levels for ACADIA Pharmaceuticals Inc.2025 Macro Impact & Verified Momentum Watchlists - newser.com
Q3 EPS Estimate for ACADIA Pharmaceuticals Cut by Analyst - MarketBeat
RBC Cuts Price Target on ACADIA Pharmaceuticals to $34 From $40, Keeps Outperform Rating - MarketScreener
Acadia Healthcare Company, Inc. Announces Chief Financial Officer Changes, Effective October 27, 2025 - MarketScreener
What drives ACADIA Pharmaceuticals Inc stock priceHead and Shoulders Patterns & Double Digit Capital Growth - earlytimes.in
Real time social sentiment graph for ACADIA Pharmaceuticals Inc.Volume Spike & Weekly Chart Analysis and Trade Guides - newser.com
Detecting price anomalies in ACADIA Pharmaceuticals Inc. with AI2025 Price Action Summary & Weekly Chart Analysis and Trade Guides - newser.com
ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish (ACAD) - Seeking Alpha
Is ACADIA Pharmaceuticals Inc. stock attractive after correctionRate Hike & Weekly High Conviction Ideas - newser.com
Wealth Enhancement Advisory Services LLC Makes New $511,000 Investment in ACADIA Pharmaceuticals Inc. $ACAD - Defense World
Intraday pattern recognizer results for ACADIA Pharmaceuticals Inc.2025 Trading Recap & Technical Entry and Exit Alerts - newser.com
Using R and stats models for ACADIA Pharmaceuticals Inc. forecastingWall Street Watch & Reliable Intraday Trade Alerts - newser.com
News impact scoring models applied to ACADIA Pharmaceuticals Inc.2025 Sector Review & Stock Portfolio Risk Control - newser.com
What machine learning models say about ACADIA Pharmaceuticals Inc.Swing Trade & Expert Verified Stock Movement Alerts - newser.com
Will ACADIA Pharmaceuticals Inc. rebound enough to break even2025 Bull vs Bear & Weekly Breakout Watchlists - newser.com
Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study - MSN
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
ACADIA Pharmaceuticals Inc. Securities Lawsuit Investigation - Claim Depot
Acadia Pharmaceuticals Inc Azioni (ACAD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Acadia Pharmaceuticals Inc Azioni (ACAD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| GAROFALO ELIZABETH A. | Director |
Sep 02 '25 |
Sale |
25.98 |
1,600 |
41,560 |
25,382 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 18 '25 |
Sale |
25.18 |
22,000 |
554,024 |
40,130 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):